Literature DB >> 16863732

Strangulation of the reconstructive gastric tube by the azygos arch.

Frank Cheau-Feng Lin1, Hyde Russell, Mark K Ferguson.   

Abstract

Graft necrosis after esophageal reconstruction is a rare but disastrous complication associated with a high mortality rate. Azygos arch strangulation of the graft is an unusual cause of graft necrosis. We report two cases of postesophagectomy gastric tube reconstruction complicated by azygos arch strangulation and graft ischemia. In one patient, graft necrosis resulted and a reconstruction was performed later with a colon interposition. In the other patient, the azygos arch was divided and the graft was preserved. We recommend dividing the azygos arch routinely during transthoracic or thoracoscopic esophagectomy if the reconstruction graft is to be brought up through the posterior mediastinal route to help avoid this problem.

Entities:  

Mesh:

Year:  2006        PMID: 16863732     DOI: 10.1016/j.athoracsur.2006.05.009

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  The resection of the azygos vein--necessary or redundant extension of transthoracic esophagectomy?

Authors:  W Schröder; D Vallböhmer; M Bludau; A Banczyk; C Gutschow; A H Hölscher
Journal:  J Gastrointest Surg       Date:  2008-02-16       Impact factor: 3.452

2.  Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.

Authors:  Keiichi Jingu; Haruo Matsushita; Ken Takeda; Rei Umezawa; Chiaki Takahashi; Toshiyuki Sugawara; Masaki Kubozono; Keiko Abe; Takaya Tanabe; Yuko Shirata; Takaya Yamamoto; Youjirou Ishikawa; Kenji Nemoto
Journal:  BMC Cancer       Date:  2012-11-22       Impact factor: 4.430

3.  Minimally invasive esophagectomy for esophageal cancer in the People's Republic of China: an overview.

Authors:  Chengchu Zhu; Ketao Jin
Journal:  Onco Targets Ther       Date:  2013-03-03       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.